SCHEMBL16335751

SCHEMBL16335751

CC1(O)CCC(NS(=O)(=O)c2ccc(-c3ccccn3)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.47
TSHR P16473 2/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
CCR6 P51684 1/20 0.43
F2 P00734 1/20 0.43
F10 P00742 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
KDM4E B2RXH2 1/20 0.41
RECQL P46063 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
RAB9A P51151 1/20 0.41
ALDH1A1 P00352 1/20 0.39
CYP3A4 P08684 1/20 0.39
KAT6A Q92794 1/20 0.39
MMP1 P03956 1/20 0.39
MMP9 P14780 1/20 0.39
MMP13 P45452 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16335707 0.84 UCHL1 (0.50) TSHRKDM4ERECQLSMN1; SMN2MEN1
SCHEMBL1723430 0.84 UCHL1 (0.50) TSHRKDM4ERECQLSMN1; SMN2MEN1
SCHEMBL21715550 0.80 SCD (0.40) CCR6F2F10MMP1MMP9
SCHEMBL23953194 0.76 APP (0.53) TSHRKDM4ERECQLSMN1; SMN2MEN1
SCHEMBL2194407 0.76 MAPK1 (0.63) TSHRLMNAGAAKDM4ERECQL
SCHEMBL2194405 0.76 MAPK1 (0.63) TSHRLMNAGAAKDM4ERECQL
SCHEMBL2194402 0.76 MAPK1 (0.63) TSHRLMNAGAAKDM4ERECQL
SCHEMBL16335530 0.73 MAP2K4 (0.46) TSHRLMNAGAAKDM4ERECQL
SCHEMBL16335531 0.73 MAP2K4 (0.46) TSHRLMNAGAAKDM4ERECQL
SCHEMBL16378447 0.73 MAP2K4 (0.41) GRM4TSHRLMNAGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025233526-A1 MITOCHONDRIAL COMPLEX I MODULATOR FOR USE IN THE TREATMENT OF ARTHRITIS ISTESSO THERAPEUTICS LIMITED (GB) 2025-11-13 WO disclosed
EP-4647071-A1 MITOCHONDRIAL COMPLEX I MODULATOR FOR USE IN THE TREATMENT OF ARTHRITIS Istesso Therapeutics Limited (GB) 2025-11-12 EP disclosed
EP-3837244-B1 1-METHYL-4-[(4-PHENYLPHENYL)SULFONYLMETHYL]CYCLOHEXYANOL AND 1-METHYL-4-[[4-(2-PYRIDYL)PHENYL]SULFONYLMETHYL]CYCLOHEXANOL COMPOUNDS AND THEIR THERAPEUTIC USE ISTESSO THERAPEUTICS LTD (GB) 2025-05-14 EP disclosed
US-12240814-B2 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexyanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylmethyl]cyclohexanol compounds and their therapeutic use ISTESSO THERAPEUTICS LIMITED (GB) 2025-03-04 US disclosed
US-12162836-B2 N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use Modern Biosciences Limited (GB) 2024-12-10 US disclosed
CN-112805270-B 1-Methyl-4- [ (4-phenylphenyl) sulfonylmethyl ] cyclohexanols and 1-methyl-4- [ [4- (2-pyridinyl) phenyl ] sulfonylmethyl ] cyclohexanols compounds and their therapeutic uses 现代生物科学有限公司 2024-10-18 CN disclosed
CN-113766953-B N-acyl- {4- [ (4-aryl-phenyl) sulfonylmethyl ] piperidine } compounds and their therapeutic uses 现代生物科学有限公司 2024-07-02 CN disclosed
US-20240182418-A1 1-Methyl-4-[(4-Phenylphenyl)Sulfonylmethyl]Cyclohexyanol And 1-Methyl-4-[[4-(2-Pyridyl)Phenyl]Sulfonylmethyl]Cyclohexanol Compounds and Their Therapeutic Use Modern Biosciences Limited (GB) 2024-06-06 US disclosed
US-11834414-B2 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexyanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylmethyl]cyclohexanol compounds and their therapeutic use Modern Biosciences Limited (GB) 2023-12-05 US disclosed
US-20230022917-A1 N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE ISTESSO THERAPEUTICS LIMITED (GB) 2023-01-26 US disclosed
US-20160145206-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4- HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE PIMCO 2664 LIMITED (GB) 2016-05-26 US disclosed
US-20160145206-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4- HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE PIMCO 2664 LIMITED (GB) 2016-05-26 US disclosed
EP-3013799-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE Pimco 2664 Limited (GB) 2016-05-04 EP disclosed
EP-3013799-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE Pimco 2664 Limited (GB) 2016-05-04 EP disclosed
CN-105492426-A N- (4-hydroxy-4-methyl-cyclohexyl) -4-phenyl-benzenesulfonamides and N- (4-hydroxy-4-methyl-cyclohexyl) -4- (2-pyridinyl) benzenesulfonamides and therapeutic uses thereof PIMCO 2664 LTD 2016-04-13 CN disclosed
CN-105492426-A N- (4-hydroxy-4-methyl-cyclohexyl) -4-phenyl-benzenesulfonamides and N- (4-hydroxy-4-methyl-cyclohexyl) -4- (2-pyridinyl) benzenesulfonamides and therapeutic uses thereof PIMCO 2664 LTD 2016-04-13 CN disclosed
CN-105492426-A N- (4-hydroxy-4-methyl-cyclohexyl) -4-phenyl-benzenesulfonamides and N- (4-hydroxy-4-methyl-cyclohexyl) -4- (2-pyridinyl) benzenesulfonamides and therapeutic uses thereof PIMCO 2664 LTD 2016-04-13 CN disclosed
WO-2014207445-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE PIMCO 2664 LIMITED (GB) 2014-12-31 WO disclosed
WO-2014207445-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE PIMCO 2664 LIMITED (GB) 2014-12-31 WO disclosed
WO-2014207445-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE PIMCO 2664 LIMITED (GB) 2014-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162836-B2 N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use MCL1, BCL9, BCL9L GRM4 137/4885TSHR 2244/4885LMNA 2924/4885
US-11834414-B2 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexyanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylmethyl]cyclohexanol compounds and their therapeutic use MALT1, BCL3, MCL1 GRM4 202/4885TSHR 1910/4885LMNA 2075/4885
US-20160145206-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4- HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE BRCA1, TPMT, SOST GRM4 908/4885TSHR 242/4885LMNA 1381/4885
US-20230022917-A1 N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE MCL1, BCL9, BCL9L GRM4 137/4885TSHR 2244/4885LMNA 2924/4885
US-12240814-B2 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexyanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylmethyl]cyclohexanol compounds and their therapeutic use MALT1, BCL3, MCL1 GRM4 202/4885TSHR 1910/4885LMNA 2075/4885
US-20240182418-A1 1-Methyl-4-[(4-Phenylphenyl)Sulfonylmethyl]Cyclohexyanol And 1-Methyl-4-[[4-(2-Pyridyl)Phenyl]Sulfonylmethyl]Cyclohexanol Compounds and Their Therapeutic Use MALT1, BCL3, MCL1 GRM4 202/4885TSHR 1910/4885LMNA 2075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.